FiercePharma
The biopharmaceutical industry is rapidly evolving, bringing fresh concepts to light every day. Subscribers turn to FiercePharma as their essential resource for the most current news, insights, and data regarding medications and the companies behind them. Each business day, FiercePharma and its associated publications provide comprehensive coverage of the pharmaceutical sector, spanning from late-stage drug development to all stages of the product lifecycle. Stay informed about topics such as regulatory approvals, negotiations with payers, manufacturing processes, marketing strategies, patent disputes, government inquiries and regulations, mergers and acquisitions, and much more.
Outlet metrics
Global
#91103
United States
#35448
Health/Health
#805
Articles
-
2 days ago |
fiercepharma.com | Zoey Becker
As part of a multi-year collaboration, GSK and India’s Bharat Biotech are redoubling their efforts to bring the world’s first malaria vaccine to more countries in need at affordable prices. Mosquirix, or RTS.S., was brought to the world stage by GSK and PATH (formerly known as Program for Appropriate Technology in Health) in 2021 as the first malaria vaccine recommended by the World Health Organization (WHO).
-
4 days ago |
fiercepharma.com | Zoey Becker
With a goal of boosting its life sciences economy into the top three of the global rankings by 2035, the U.K. government is laying out six specific areas of focus to bolster its growth in the industry. The interventions (PDF) come via the government’s new “Modern Industrial Strategy,” which prioritizes eight high-growth sectors and builds on a previous “Invest 2035” plan that was floated last year.
-
4 days ago |
fiercepharma.com | Eric Sagonowsky
Only a few days after reports emerged that the director of the FDA's cell and gene therapy office had been abruptly put on administrative leave, a new departure shows that an intense period of leadership turnover at the agency isn't over. On Monday, Jacqueline Corrigan-Curay, the acting director of the Center for Drug Evaluation and Research (CDER), wrote in an email to colleagues that she'd be retiring from the agency in July, according to reports in Bloomberg, Endpoints News and Stat.
-
4 days ago |
fiercepharma.com | Fraiser Kansteiner
With detailed readouts from a suite of late-stage trials now on tap, Eli Lilly is heading to regulators in pursuit of a green light for its once-a-week insulin asset efsitora alfa.
-
1 week ago |
fiercepharma.com | Zoey Becker
As the saying goes, “If you don’t laugh, you’ll cry.” Biogen and ad agency 21Grams took that mantra to heart with their Gold Pharma Lions–winning social media campaign, “Friedreich’s Back,” for Friedreich’s ataxia (FA) treatment Skyclarys. At this year’s Cannes Lions International Festival of Creativity, they shared how they walked the fine line of humor in drug advertising.
FiercePharma journalists
Contact details
Address
123 Example Street
City, Country 12345
Phone
+1 (555) 123-4567
Email Patterns
Website
http://fiercepharma.comTry JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →